Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Luxna Biotech Co. Ltd. operates within the Biotechnology & Pharmaceuticals technology area. Currently, the patent prosecution profile for this entity shows 1 pending office action. This specific count of 1 pending office action reflects the current workload assigned to the legal team managing these assets at the USPTO.
The data indicates that there is 1 distinct examiner and 1 distinct art unit involved in the review process. The busiest examiner for this portfolio is PERSONS, JENNA L, who is responsible for 1 pending office action. Having 1 distinct examiner and 1 distinct art unit means that the prosecution is confined to a specific technical group and a single individual's review standards.
Practitioners working in the Biotechnology & Pharmaceuticals technology area must tailor their responses to the specific preferences of PERSONS, JENNA L. Because there is only 1 distinct examiner, the strategy does not need to account for different examination styles. This focused approach is a key characteristic of the current prosecution for Luxna Biotech Co. Ltd.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PERSONS, JENNA L | 1 | 50.8% | +61.7% |
| ZARA, JANE J | 1 | 71.0% | +16.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035300 | Agent for Regulating Expression and/or Function of RPS25 Gene | ZARA, JANE J | 22d |
| 18558056 | METHOD FOR DESIGNING OLIGONUCLEOTIDE HAVING REDUCED CENTRAL TOXICITY | PERSONS, JENNA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035300 | Agent for Regulating Expression and/or Function of RPS25 Gene | ZARA, JANE J | 22d |
| 18558056 | METHOD FOR DESIGNING OLIGONUCLEOTIDE HAVING REDUCED CENTRAL TOXICITY | PERSONS, JENNA L | — |
| Art Unit | Apps |
|---|---|
| 1637 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18558056 | METHOD FOR DESIGNING OLIGONUCLEOTIDE HAVING REDUCED CENTRAL TOXICITY | PERSONS, JENNA L | 1637 | §101§102§103§112DP | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18035300 | Agent for Regulating Expression and/or Function of RPS25 Gene | ZARA, JANE J | 1637 | §103§112 | Final Rejection | 22d | Pending | May 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial